Abstract: The present invention provides a method for quantifying the presence of extracellular LBP in body fluids including blood in a subject comprising conducting an LBP immunoassay on plasma obtained from said subject.
Type:
Grant
Filed:
November 26, 2001
Date of Patent:
July 25, 2006
Assignee:
Xoma Corporation
Inventors:
Mark Leslie White, Stephen Fitzhugh Carroll, Jeremy Kam-kuen Ma
Abstract: The present invention relates to methods for treating a subject suffering from infection with Mycobacteria, such as M. leprae or M. tuberculosis comprising administering to the subject a composition comprising a bactericidal/permeability-inducing (BPI) protein product alone or in combination with administration of an anti-Mycobacterial antibiotic.
Abstract: Disclosed are novel bactericidal/permeability-increasing (BPI) protein products wherein cysteine residue number 132 or 135 is replaced by another amino acid residue, preferably an alanine or serine residue and/or wherein the leucine residue at position 193 is the carboxy terminal residue. Also disclosed are DNA sequences encoding methods for the production of the same in appropriate host cells, and stable homogeneous pharmaceutical compositions containing the analogs suitable for use treatment of gram negative bacterial infection and its sequelae.
Type:
Grant
Filed:
July 16, 2002
Date of Patent:
December 7, 2004
Assignee:
Xoma Corporation
Inventors:
Georgia Theofan, Arnold Horwitz, David Burke, Manik Baltaian, Lynn Grinna
Abstract: The present invention provides methods of treating adverse physiological effects associated with intestinal ischemia/reperfusion by administering to a subject suffering from the effects of intestinal ischemia/reperfusion an effective amount of a BPI protein product.
Type:
Grant
Filed:
October 12, 1999
Date of Patent:
July 27, 2004
Assignee:
Xoma Corporation
Inventors:
William Steve Ammons, Károly M. Mészäros
Abstract: The present invention provides a method for quantifying the presence of extracellular BPI in body fluids including blood in a subject comprising conducting a BPI immunoassay on body fluid sample obtained from said subject.
Type:
Grant
Filed:
October 9, 1998
Date of Patent:
July 6, 2004
Assignee:
XOMA Corporation
Inventors:
Mark Leslie White, Stephen Fitzhugh Carroll, Jeremy Kam-kuen Ma
Abstract: The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and variants of the sequence or subsequence thereof, having at least one of the BPI biological activities, such as heparin binding, heparin neutralization, LPS binding, LPS neutralization or bactericidal activity. The invention provides peptides and pharmaceutical compositions of such peptides for a variety of therapeutic uses.
Abstract: The present invention provides methods of treating adverse physiological effects associated with depressed reticuloendothelial system function comprising administering to a subject suffering from depressed reticuloendothelial system function an effective amount of a BPI protein product.
Type:
Grant
Filed:
October 12, 2000
Date of Patent:
February 3, 2004
Assignee:
Xoma Corporation
Inventors:
Paul A. M. van Leeuwan, Marja A. Boermeester
Abstract: The present invention relates generally to anti-fungal peptides derived from or based on Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI) and in vivo or in vitro uses of such peptides.
Type:
Grant
Filed:
October 2, 2000
Date of Patent:
December 16, 2003
Assignee:
Xoma Corporation
Inventors:
Roger G. Little, II, Edward Lim, Mitchell B. Fadem
Abstract: The present invention relates to methods for treating a subject suffering from infection with Mycobacteria, such as M. leprae or M. tuberculosis comprising administering to the subject a composition comprising a bactericidal/permeability-inducing (BPI) protein product alone or in combination with administration of an anti-Mycobacterial antibiotic.
Abstract: Antithrombotic materials and methods are provided for the treatment of thrombotic disorders, in which therapeutically effective amounts of BPI protein products are administered.
Abstract: Novel BPI deletion analogs are provided that consist of amino acid residues 10 through 193 of mature human BPI wherein the cysteine residue at BPI amino acid position 132 is replaced by another amino acid. Fusion proteins comprising these analogs are also provided, as are polynucleotides encoding these products, materials and methods for their recombinant production, compositions and medicaments of these products, and therapeutic uses for these products.
Type:
Grant
Filed:
May 25, 2000
Date of Patent:
July 29, 2003
Assignee:
Xoma Corporation
Inventors:
Arnold Horwitz, Stephen F. Carroll, David Burke
Abstract: Methods and materials for the treatment of human meningococcemia are provided in which therapeutically effective amounts of BPI protein products are administered.
Abstract: Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytokines, fibrinolysis and coagulation factors and changes in lymphocyte counts are observed upon such treatment. Also observed is alleviation of endotoxin mediated decreases in systemic vascular resistance index (SVRI) and concomitant increases in cardiac index (CI).
Type:
Grant
Filed:
December 8, 2000
Date of Patent:
July 1, 2003
Assignee:
Xoma Corporation
Inventors:
Nadav Friedmann, Patrick J. Scannon, Sander J. H. van Deventer, Marijke A. M. von der Mohlen, Nancy Wedel
Abstract: The present invention relates to methods for treating chlamydial infection comprising administering to a subject suffering from a chlamydial infection a bactericidal permeability-inducing (BPI) protein product.
Abstract: The present invention provides methods of treating a subject suffering from adverse effects, complications or conditions, associated with or resulting from a corneal injury including, corneal infection or ulceration, by topical administration of suitable ophthalmic preparations of bactericidal/permeability-increasing (BPI) protein products.
Abstract: Improved therapeutic uses for N-terminal BPI protein products are described in patients that have BPI-reactive anti-neutrophil cytoplasmic antibodies.
Abstract: The present invention provides methods of treating a subject suffering from adverse effects, complications or conditions, associated with or resulting from a corneal injury including, corneal infection or ulceration, by topical administration of suitable ophthalmic preparations of bactericidal/permeability-increasing (BPI) protein products.
Abstract: The present invention provides a method for quantifying the presence of extracellular LBP in body fluids including blood in a subject comprising conducting an LBP immunoassay on plasma obtained from said subject.
Type:
Application
Filed:
November 26, 2001
Publication date:
September 12, 2002
Applicant:
XOMA Corporation
Inventors:
Mark Leslie White, Stephen Fitzhugh Carroll, Jeremy Kam-Kuen Ma